Hims & Hers Health, Inc. research snapshot
HIMS AI stock analysis currently reads Hims & Hers as a scaled consumer health platform with nearly 2.6 million subscribers, expanding international revenue, and a 2026 revenue guide of $2.8 billion to $3.0 billion. The counterweight is visible in the same data: Q1 2026 revenue grew only 4% year over year, United States revenue fell 8%, gross margin fell to 65%, and GAAP net income turned into a $92.1 million loss after a strategic weight-loss supply chain pivot. The HIMS AI stock forecast is therefore a range of conditional outcomes, not a precise price promise. It depends on branded GLP-1 execution, regulatory treatment of compounded products and peptides, international integration, margin recovery, and management capital allocation.
Current price
$34.38 closing price on July 10, 2026
Market cap
$7.96 billion reported equity value on July 10, 2026
AI score
64 / 100
Rating
High-growth consumer health platform with elevated regulatory, margin, and valuation risk
Trend status
Short-term weakness below the 20-day and 50-day averages, while price remains above the 200-day trend area after a volatile GLP-1 repricing
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Hims & Hers combines telehealth consultations, recurring prescription products, diagnostics, fulfillment, and consumer health content in a direct-to-consumer platform. | High |
| Moat | Brand recognition, subscriber data, recurring workflows, provider and pharmacy relationships, and a growing multi-specialty platform create a useful moat, but much of the care and fulfillment infrastructure can be competed away. | Medium |
| Management | Co-founder and CEO Andrew Dudum has substantial economic and voting influence. The team has shown willingness to invest and pivot quickly, but the YourBio and Eucalyptus transactions, GLP-1 pivot, and dual-class control raise capital allocation and governance questions. | Medium |
| Financial trend | FY2025 revenue rose 59% to $2.35 billion and operating cash flow reached $300.0 million, but Q1 2026 revenue growth slowed to 4%, gross margin fell to 65%, and GAAP net income was negative $92.1 million. | High |
| Valuation | At $34.38, the stock was about 3.29 times FY2025 sales, 60.32 times FY2025 basic EPS, and 134.74 times FY2025 company-defined free cash flow per share. The multiple is not a bargain if the 2026 transition lasts longer than expected. | High for reported inputs |
| Technical trend | Price was below the 20-day and 50-day simple moving averages but above the 200-day average on July 10. RSI was near 32, so the setup was weak and near oversold rather than a confirmed reversal. | Medium |
| Risk level | Risk is high because healthcare regulation, product safety, privacy, advertising, GLP-1 supply, gross margin, international integration, leverage, and CEO control can all affect the thesis. | High |
| AI confidence | Descriptive confidence is high for audited and company-reported numbers, while the normalized earnings and scenario model remain assumption-sensitive. | High data confidence |
| Investment certainty | HIMS may compound if it turns subscriber scale into durable retention, better unit economics, and profitable international growth, but the current evidence does not support high certainty. | Medium-low |
HIMS AI stock forecast
The HIMS AI stock forecast uses the July 10 closing price of $34.38 and FY2025 basic EPS of $0.57 as a normalized starting point because Q1 2026 GAAP earnings were distorted by a strategic pivot and restructuring charges. A three-year model using exact financial_rigor.py arithmetic produced a central output near $29.5, an optimistic output near $63.1, and a pessimistic output near $5.3. The page shows broader ranges around those outputs because actual results can differ materially.
$55 to $70
More likely if Q2 and full-year revenue land near the upper end of guidance, branded GLP-1 demand scales without major regulatory setbacks, international acquisitions integrate well, subscriber retention improves, and normalized EPS compounds near 35% with a 45x exit multiple.
$26 to $33
More likely if 2026 revenue reaches the middle of the $2.8 billion to $3.0 billion guide, gross margin stays under pressure during investment, GAAP profitability returns later, and normalized EPS compounds near 20% while the valuation settles near 30x.
$4 to $8
More likely if United States demand remains weak, compounded and branded weight-loss economics disappoint, regulatory or legal costs rise, acquisitions increase dilution or leverage, and normalized EPS declines near 15% with a 15x exit multiple.
HIMS AI technical analysis
HIMS AI technical analysis was neutral to bearish in the short term as of the July 10, 2026 close. Price at $34.38 was below the 20-day SMA near $35.76 and the 50-day SMA near $36.42, but above the 200-day SMA near $31.53. The 14-day RSI was about 32.03, which signals weak momentum and near-oversold conditions rather than a confirmed reversal. July 10 volume was 11.8 million shares, below the largest recent June and July volume spikes, so a rebound still needs participation confirmation.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $34.38 | July 10, 2026 closing price used as the data cutoff market reference. |
| Near support | $33.18 to $33.40 | The July 10 low and daily pivot support references form the first pullback area. |
| Trend support | $31.53 | The 200-day SMA reported for July 10 is the key longer-trend reference. |
| Deeper support | $28.68 to $29.50 | The 50-day SMA and the lower edge of the recent June to July range sit near this zone. |
| Near resistance | $35.05 to $35.76 | The 5-day and 20-day SMAs are the first overhead resistance references after the close. |
| Major resistance | $36.42 to $39.05 | The 50-day SMA and the July 7 and July 6 highs define the next overhead zone. |
| Moving averages | 20-day $35.76, 50-day $36.42, 200-day $31.53 | Price was below the 20-day and 50-day averages but above the 200-day average at the cutoff, a mixed setup with short-term weakness. |
| Momentum | Weak, RSI near 32.03 | The reported 14-day RSI was close to oversold territory, but an oversold reading is not a reversal signal by itself. |
| Volume | 11.8M shares on July 10 | The close occurred below the largest recent June and July volume spikes, so a resistance break should be judged with stronger participation. |
| Volatility | High | HIMS is sensitive to FDA and state healthcare actions, GLP-1 headlines, earnings, short-term positioning, and changes in growth-stock multiples. |
| Invalidation | Daily close below $31.53, then $28.68 | A break below the 200-day area weakens the long-term trend read; a break below the 50-day support zone would deepen the bearish setup. |
HIMS AI trading strategy
The HIMS AI trading strategy below is a rules-based research framework, not personalized advice. It links technical levels to subscriber growth, United States revenue, branded and compounded GLP-1 economics, gross margin, free cash flow, regulatory developments, and acquisition integration.
Watch for a close above $35.76 to $39.05 on volume above the recent average while the next earnings update confirms revenue acceleration, subscriber retention, healthy free cash flow, and a credible path through the gross margin reset.
A failed rebound followed by a close below the first support zone near $33.18 should reduce confidence. A close below $31.53 weakens the longer trend, especially if United States revenue or guidance also deteriorates.
If HIMS pulls back toward $28.68 to $33.40 without a guidance cut or adverse regulatory development, compare the price with subscriber growth, cash flow, 2026 revenue guidance, normalized earnings, and the value of the international platform.
Do not treat a technical pullback as benign if branded GLP-1 access weakens, compounded product liabilities rise, gross margin falls further, or acquisition payments increase dilution and debt pressure.
Track United States and rest-of-world revenue, subscribers, monthly revenue per average subscriber, retention, marketing as a percentage of revenue, gross margin, adjusted EBITDA, free cash flow, cash and investments, debt, share count, regulatory actions, and Eucalyptus integration.
Position sizing should reflect that HIMS is a high-volatility healthcare growth stock. The 2030 targets of at least $6.5 billion revenue and $1.3 billion adjusted EBITDA are management targets, not guaranteed outcomes.
Investment research summary
Customers pay Hims & Hers for lower-friction access to health consultations, prescriptions, diagnostics, and recurring treatment plans. The economic engine is a subscription workflow that combines consumer acquisition, provider access, product fulfillment, and follow-up data across specialties such as sexual health, dermatology, mental health, weight loss, and women's health.
The strongest moat is the combination of brand, recurring customer relationships, first-party health and treatment data, provider and pharmacy operations, and cross-selling across specialties. Switching costs are real but limited because consumers can use other telehealth providers, pharmacies, retailers, or direct pharmaceutical channels.
The thesis fails if healthcare rules restrict compounding or marketing, product safety or privacy incidents damage trust, United States growth stays weak, GLP-1 economics remain low margin, or acquisitions create integration costs and dilution faster than they add durable cash flow. The main question is not whether HIMS can grow, but whether growth remains profitable after the easy demand and favorable product mix fade.
Andrew Dudum is co-founder, CEO, chairman, and a major Class V holder. The 2026 proxy reported 87.73% of total voting power for Dudum as of April 16, 2026, so alignment and control are both unusually high. Management has acted decisively on products, acquisitions, technology, and share repurchases, but the same speed creates governance and capital allocation risk.
Consumer healthcare is moving toward digital intake, telehealth, at-home diagnostics, personalized treatment, and direct access to branded medicines. HIMS is positioned in that transition, but the platform depends on licensed providers, pharmacy and supply-chain partners, advertising channels, and rules that can change quickly. Its international expansion through Zava, Medici, and the completed June 2, 2026 Eucalyptus acquisition increases opportunity and complexity.
At $34.38, HIMS traded at 3.29 times FY2025 sales and 134.74 times FY2025 company-defined free cash flow per share using exact financial_rigor.py inputs. Net cash is negative after convertible notes and lease obligations, so revenue growth alone is not enough. Margin of safety improves if the company converts subscriber scale into durable free cash flow and normalized EPS; it weakens if the 2026 transition becomes a longer period of low-margin growth.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| HIMS closing price | $34.38 on July 10, 2026 | StockAnalysis historical prices | July 12, 2026 |
| Market capitalization | $7.96 billion on July 10, 2026 | StockAnalysis market cap | July 12, 2026 |
| Market cap cross-check | $7.94 billion calculated from $34.38 and 231.071 million shares, 0.20% below reported market cap | SEC proxy ownership data and financial_rigor.py | July 12, 2026 |
| Q1 2026 revenue and subscribers | $608.1 million revenue, 2.584 million subscribers, and 4% revenue growth | Hims & Hers Q1 2026 results | July 12, 2026 |
| Q1 2026 revenue geography | $529.9 million United States revenue, down 8%, and $78.2 million rest-of-world revenue, up 969% | Hims & Hers Q1 2026 results | July 12, 2026 |
| FY2025 financial history | $2.348 billion revenue, $128.4 million net income, and 74% gross margin | SEC 2025 Form 10-K and StockAnalysis financials | July 12, 2026 |
| FY2025 cash generation | $300.0 million operating cash flow and $57.4 million company-defined free cash flow; StockAnalysis reports $73.96 million standardized free cash flow because its formula excludes purchases of intangible assets | SEC FY2025 earnings release and StockAnalysis cash flow statement | July 12, 2026 |
| Q1 2026 liquidity and debt | $750.9 million cash and short-term investments, $974.1 million convertible senior notes, and $446.2 million stockholders' equity at March 31, 2026; excludes subsequent financing and acquisition effects | Hims & Hers Q1 2026 Form 10-Q | July 12, 2026 |
| Eucalyptus acquisition | Completed June 2, 2026; transaction consideration can include cash, deferred payments, and earn-outs | Hims & Hers acquisition completion release | July 12, 2026 |
| June 2026 convertible notes | $350 million upsized convertible senior notes offering announced to support international expansion and AI-driven platform investment | Hims & Hers investor release | July 12, 2026 |
| 2026 management guidance | $2.8 billion to $3.0 billion revenue and $275 million to $350 million adjusted EBITDA | Hims & Hers Q1 2026 results | July 12, 2026 |
| Technical references | 20-day SMA $35.76, 50-day SMA $36.42, 200-day SMA $31.53, 14-day RSI about 32.03 | Investing.com technical analysis | July 12, 2026 |
| July 10 volume | 11.8 million shares on July 10, 2026 | StockAnalysis historical prices | July 12, 2026 |
| Management control | Andrew Dudum reported 87.73% of total voting power as of April 16, 2026 | Hims & Hers 2026 proxy statement | July 12, 2026 |
| Valuation math | 60.32x FY2025 basic EPS, 134.74x FY2025 company-defined FCF per share, and 3.29x FY2025 sales from financial_rigor.py | financial_rigor.py exact arithmetic using SEC and StockAnalysis inputs | July 12, 2026 |
This HIMS AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong. Market prices and technical levels may change after publication.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
